Edwina Light
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Edwina Light has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Ian Kerridge
The University of Sydney, Sydney, Australia
13 shared publications - Christopher James Ryan
University of New South Wales
8 shared publications - Wendy Lipworth
Department of Philosophy, Macquarie University, Sydney, NSW, Australia
8 shared publications - Lisa Dive
Graduate School of Health, University of Technology Sydney, Sydney, New South Wales, Australia
6 shared publications - Glenn E. Hunt
Discipline of Psychiatry Concord Clinical School The University of Sydney Sydney NSW Australia
5 shared publications Michael Robertson
University of Sydney
5 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by SAGE Publications in Australian & New Zealand Journal of Psychiatry
Variables associated with variations in compulsory community treatment by health districts: A meta-regression analysis across four Australian jurisdictions
Objective: The use of compulsory community treatment in Australia varies widely within, and across, jurisdictions for reasons that are not fully understood. This study, therefore, used meta-regression to explore possible explanations for this variation in the following four Australian states: Queensland, South Australia, New South Wales and Victoria. Methods: Aggregated administrative data from the Australian Institute of Health and Welfare for 2018 were analysed, encompassing 402,060 individuals in contact with community mental health services. Meta-regression using logit-transformed proportions was employed to assess associations between compulsory community treatment rates and district-level sociodemographic variables, including age, sex, marital status, region of birth and metropolitan residence. Workforce data were also examined in New South Wales. Results: Compulsory community treatment use varied significantly by jurisdiction and by health district within jurisdictions. Higher rates were associated with districts having more individuals aged 25–44 years, males (in South Australia), metropolitan residents, and those born outside Oceania. These associations persisted after adjustment. There was no statistically significant association between workforce levels and compulsory community treatment use in New South Wales. Conclusion: Our findings suggest that sociodemographic factors such as age, sex and place of residence or birth may explain some of the variation in compulsory community treatment use between health districts. The influence of sociodemographic variables and geographical location in influencing compulsory community treatment use at the health district level needs further investigation. Registration: Australian and New Zealand Clinical Trials Registry ( https://www.anzctr.org.au/ ; ACTRN12624000153516).
- 30 September 2026
- Published by SAGE Publications in Australian & New Zealand Journal of Psychiatry
Open AccessVariables associated with variations in compulsory community treatment by health districts: A meta-regression analysis across four Australian jurisdictions
Objective: The use of compulsory community treatment in Australia varies widely within, and across, jurisdictions for reasons that are not fully understood. This study, therefore, used meta-regression to explore possible explanations for this variation in the following four Australian states: Queensland, South Australia, New South Wales and Victoria. Methods: Aggregated administrative data from the Australian Institute of Health and Welfare for 2018 were analysed, encompassing 402,060 individuals in contact with community mental health services. Meta-regression using logit-transformed proportions was employed to assess associations between compulsory community treatment rates and district-level sociodemographic variables, including age, sex, marital status, region of birth and metropolitan residence. Workforce data were also examined in New South Wales. Results: Compulsory community treatment use varied significantly by jurisdiction and by health district within jurisdictions. Higher rates were associated with districts having more individuals aged 25–44 years, males (in South Australia), metropolitan residents, and those born outside Oceania. These associations persisted after adjustment. There was no statistically significant association between workforce levels and compulsory community treatment use in New South Wales. Conclusion: Our findings suggest that sociodemographic factors such as age, sex and place of residence or birth may explain some of the variation in compulsory community treatment use between health districts. The influence of sociodemographic variables and geographical location in influencing compulsory community treatment use at the health district level needs further investigation. Registration: Australian and New Zealand Clinical Trials Registry ( https://www.anzctr.org.au/ ; ACTRN12624000153516).
- Open Access
- 17 July 2026
- Published by Wiley in Health Expectations
- Vol. 29 (4) , e70770
‘Traumatic to Say the Least; It Still Affects Me’: Consumer Perspectives on Community Treatment Orders in Australia
Background: Community Treatment Orders (CTOs) are contested practices in mental healthcare due to unresolved evidence of effectiveness and persistent human rights concerns. Despite this, Australia has high rates of CTO use internationally. Research from a lived and living experience (LLE) perspective remains limited. Methods: This mixed methods research explored experiences of people with LLE of mental ill‐health and being on a CTO (‘consumers’). An online survey including Likert‐rated, categorical and open‐ended questions was disseminated across Australia in 2024 to consumers aged 18 years or over. Quantitative data were reported descriptively, and qualitative data were analysed using Latent Content Analysis. Results: Forty‐three people completed the survey; most identified as female (86%); 51.2% were aged 30‐49 years; 7.2% were currently on a CTO; 40.5% had been on a CTO in the past 1‐5 years; and 45.2% had been on a CTO more than once. Automated data contamination (‘bot’) infiltration hampered inclusion of further data. Participant responses included: (1) experiences prior to being on a CTO; (2) experiences whilst on a CTO; (3) attitudes towards CTOs; (4) family involvement; and (5) views on mental health services. While some consumers reported experiencing positive care, many rejected use of CTOs, reporting coercion, exclusion from decision‐making and information, lack of alternative support options, and lack of compassion. Conclusions: Policy and practice reforms, including focus on recovery and human rights, appear to have failed to improve experiences of CTOs. Further work to close the policy‐practice gap and translate policy into more inclusive, human rights‐based care is indicated. Lived Experience or Public Contributions: This project has included considerable involvement and community engagement with people with lived and living experience (‘LLE’) of CTOs and/or mental health service use in all phases of the project. The project includes two Chief Investigators who identify as LLE leaders and researchers (VE and SL), and who have direct lived experience of CTOs, or as a family/caregiver of individuals who have direct lived experience of CTOs. The project manager (TZ) and some project staff (TS, TK, and PS) are LLE researchers, and the project is guided by a Lived Experience Advisory Panel (LEAP) with LLE experience of CTOs, including both service users and family/caregivers. We also have LLE experts on our project's international advisory panel. Together, their contributions have been vital in the project team's open and transparent reflections on their diverse perspectives and positioning which have grounded the project's focus on LLE perspectives.
- 17 July 2026
- Published by Wiley in Health Expectations
- Vol. 29 (4) , e70770
Open Access‘Traumatic to Say the Least; It Still Affects Me’: Consumer Perspectives on Community Treatment Orders in Australia
Background: Community Treatment Orders (CTOs) are contested practices in mental healthcare due to unresolved evidence of effectiveness and persistent human rights concerns. Despite this, Australia has high rates of CTO use internationally. Research from a lived and living experience (LLE) perspective remains limited. Methods: This mixed methods research explored experiences of people with LLE of mental ill‐health and being on a CTO (‘consumers’). An online survey including Likert‐rated, categorical and open‐ended questions was disseminated across Australia in 2024 to consumers aged 18 years or over. Quantitative data were reported descriptively, and qualitative data were analysed using Latent Content Analysis. Results: Forty‐three people completed the survey; most identified as female (86%); 51.2% were aged 30‐49 years; 7.2% were currently on a CTO; 40.5% had been on a CTO in the past 1‐5 years; and 45.2% had been on a CTO more than once. Automated data contamination (‘bot’) infiltration hampered inclusion of further data. Participant responses included: (1) experiences prior to being on a CTO; (2) experiences whilst on a CTO; (3) attitudes towards CTOs; (4) family involvement; and (5) views on mental health services. While some consumers reported experiencing positive care, many rejected use of CTOs, reporting coercion, exclusion from decision‐making and information, lack of alternative support options, and lack of compassion. Conclusions: Policy and practice reforms, including focus on recovery and human rights, appear to have failed to improve experiences of CTOs. Further work to close the policy‐practice gap and translate policy into more inclusive, human rights‐based care is indicated. Lived Experience or Public Contributions: This project has included considerable involvement and community engagement with people with lived and living experience (‘LLE’) of CTOs and/or mental health service use in all phases of the project. The project includes two Chief Investigators who identify as LLE leaders and researchers (VE and SL), and who have direct lived experience of CTOs, or as a family/caregiver of individuals who have direct lived experience of CTOs. The project manager (TZ) and some project staff (TS, TK, and PS) are LLE researchers, and the project is guided by a Lived Experience Advisory Panel (LEAP) with LLE experience of CTOs, including both service users and family/caregivers. We also have LLE experts on our project's international advisory panel. Together, their contributions have been vital in the project team's open and transparent reflections on their diverse perspectives and positioning which have grounded the project's focus on LLE perspectives.
- Open Access
- 22 May 2025
- Published by Elsevier in Australian Critical Care
- Vol. 38 (4) , 101254
Critical care nurses’ responses to clinical scenarios involving cardiopulmonary resuscitation for deceased inpatients without a Do Not Resuscitate order: A cross-sectional study
- 22 May 2025
- Published by Elsevier in Australian Critical Care
- Vol. 38 (4) , 101254
Open AccessCritical care nurses’ responses to clinical scenarios involving cardiopulmonary resuscitation for deceased inpatients without a Do Not Resuscitate order: A cross-sectional study
- Open Access
- 2 January 2024
- Published by Springer Nature in Journal of Bioethical Inquiry
- Vol. 20 (4) , 1-4
Lead Essay—Viral Trajectories
- 2 January 2024
- Published by Springer Nature in Journal of Bioethical Inquiry
- Vol. 20 (4) , 1-4
Open AccessLead Essay—Viral Trajectories
- Open Access
- 14 December 2023
- Published by Wiley in Internal Medicine Journal
- Vol. 54 (5) , 724-734
Clinician perspectives on voluntary assisted dying and willingness to be involved: a multisite, cross‐sectional survey during implementation in New South Wales, Australia
Background: In the context of nationwide law reform, New South Wales (NSW) became the last state in Australia to legalise voluntary assisted dying (VAD) – commencing 28 November 2023. Clinicians have divergent views regarding VAD, with varying levels of understanding, support, and willingness to be involved, and these may have a significant impact on the successful implementation.Aims: To understand levels of support, understanding and willingness to be involved in VAD among clinical staff across NSW during implementation of VAD.Methods: A multisite, cross‐sectional online survey of clinicians across four local health districts, assessing relevant demographics, awareness of and support for VAD legislation and willingness to be involved in different levels of VAD‐related clinical activities.Results: A total of 3010 clinical staff completed the survey. A majority of participants were aware of VAD legislation in NSW (86.35%) and supportive of it (76%), with nursing and allied health clinicians significantly more likely than medical specialists to express support. Among medical specialists, support was statistically more likely in those who did not care for patients at the end of life and those with limited knowledge of the legislation. Willingness of medical specialists to perform key roles was significantly lower, with 41.49% willing to act in coordinating or consulting roles, and only 23.21% as administering practitioners.Conclusions: The majority of clinical staff surveyed across NSW supported VAD legislation. While many eligible clinicians were reluctant to be actively involved, sufficient numbers appear willing to provide VAD services, indicating that successful implementation should be possible.
- 14 December 2023
- Published by Wiley in Internal Medicine Journal
- Vol. 54 (5) , 724-734
Open AccessClinician perspectives on voluntary assisted dying and willingness to be involved: a multisite, cross‐sectional survey during implementation in New South Wales, Australia
Background: In the context of nationwide law reform, New South Wales (NSW) became the last state in Australia to legalise voluntary assisted dying (VAD) – commencing 28 November 2023. Clinicians have divergent views regarding VAD, with varying levels of understanding, support, and willingness to be involved, and these may have a significant impact on the successful implementation.Aims: To understand levels of support, understanding and willingness to be involved in VAD among clinical staff across NSW during implementation of VAD.Methods: A multisite, cross‐sectional online survey of clinicians across four local health districts, assessing relevant demographics, awareness of and support for VAD legislation and willingness to be involved in different levels of VAD‐related clinical activities.Results: A total of 3010 clinical staff completed the survey. A majority of participants were aware of VAD legislation in NSW (86.35%) and supportive of it (76%), with nursing and allied health clinicians significantly more likely than medical specialists to express support. Among medical specialists, support was statistically more likely in those who did not care for patients at the end of life and those with limited knowledge of the legislation. Willingness of medical specialists to perform key roles was significantly lower, with 41.49% willing to act in coordinating or consulting roles, and only 23.21% as administering practitioners.Conclusions: The majority of clinical staff surveyed across NSW supported VAD legislation. While many eligible clinicians were reluctant to be actively involved, sufficient numbers appear willing to provide VAD services, indicating that successful implementation should be possible.
- Open Access
- 8 July 2022
- Published by Springer Nature
- p. 129-152
Bioethics and the Krankenmorde: Disability and Diversity
Between 1933 and 1945, almost 300,000 people were murdered and 360,000 sterilized by the National Socialist (Nazi) regime under a group of crimes now collectively known as the Krankenmorde, the murder of the sick and disabled. Founded in narrow-minded and inconsistent accounts of a good and valuable life, the Nazi eugenic and “euthanasia” crimes were brutal and violent acts organized and executed by doctors, nurses and other professionals. Acknowledgement of this group of victims was delayed and obscured due to historical events as well as prevailing political and social attitudes toward mental illness and disability. As a result, the breadth of the Krankemorde crimes and its victims, its relationship to the Holocaust and its contemporary significance–to bioethics and society more broadly–is less recognized or understood than that of other Nazi medical crimes, such as the infamous experiments on prisoners. First presenting a history of the Krankenmorde and its aftermath in Germany and Nazi occupied territories, this chapter goes on to examine the value of bioethics having better knowledge of this part of its history and, in particular, engaging with its own epistemic constraints in relation to disability and ableism. These ideas are explored further in the context of contemporary bioethical issues related to the rights and treatment of people with disabilities, specifically the allocation of health resources. Throughout the chapter we seek to highlight the lives of Krankenmorde victims–those who survived and those who did not–all of whom have been historically overlooked and marginalized.
- 8 July 2022
- Published by Springer Nature
- p. 129-152
Open AccessBioethics and the Krankenmorde: Disability and Diversity
Between 1933 and 1945, almost 300,000 people were murdered and 360,000 sterilized by the National Socialist (Nazi) regime under a group of crimes now collectively known as the Krankenmorde, the murder of the sick and disabled. Founded in narrow-minded and inconsistent accounts of a good and valuable life, the Nazi eugenic and “euthanasia” crimes were brutal and violent acts organized and executed by doctors, nurses and other professionals. Acknowledgement of this group of victims was delayed and obscured due to historical events as well as prevailing political and social attitudes toward mental illness and disability. As a result, the breadth of the Krankemorde crimes and its victims, its relationship to the Holocaust and its contemporary significance–to bioethics and society more broadly–is less recognized or understood than that of other Nazi medical crimes, such as the infamous experiments on prisoners. First presenting a history of the Krankenmorde and its aftermath in Germany and Nazi occupied territories, this chapter goes on to examine the value of bioethics having better knowledge of this part of its history and, in particular, engaging with its own epistemic constraints in relation to disability and ableism. These ideas are explored further in the context of contemporary bioethical issues related to the rights and treatment of people with disabilities, specifically the allocation of health resources. Throughout the chapter we seek to highlight the lives of Krankenmorde victims–those who survived and those who did not–all of whom have been historically overlooked and marginalized.
- 20 November 2020
- Published by CSIRO Publishing in Australian Health Review
- Vol. 45 (2) , 214-222
Biobank networking and globalisation: perspectives and practices of Australian biobanks
Objective: This study examined the practices and attitudes of Australian biobanks regarding access to samples and data, as well as local and global networking with other biobanks. Methods: This was a mixed-methods study, including an online survey of Australian biobank administrators and qualitative interviews with survey participants. The survey examined the criteria applied when considering requests to share or network. The interviews explored attitudes and practices regarding sharing and networking. Results: Most (90.9%; 30/33) biobanks offered access to their samples and data to others, principally for research (90.6%; 29/32). The most common criteria used to evaluate access requests included ethical oversight (84.8%; 28/33), scientific merit (84.8%; 28/33) and intended use (81.8%; 27/33). Just over two-thirds (69.7%; 23/33) of biobanks participated in Australian networks, and 39.1% (9/23) participated in global networks. Networking took the form of both sharing standardised operating procedures and policies (60.9%) and sharing samples and data (43.5%). Thirteen of the 16 interviewees participated in networks. Motivations for sharing included scientific necessity, sharing expertise and standardising operations and governance. Significant barriers to networking remain, including insufficient resources, inconsistent regulations and procedures, and cultural and political issues to do with the conduct of research. Conclusions: Many Australian biobanks are already active participants in various types of global biobanking. If biobanks are to expand and make the most of their involvement in global networks, then important barriers need to be overcome. What is known about the topic?: Biobanks that store human tissue and associated data are increasingly forming local, national and global networks. These networks create opportunities for enhancing the utility and sustainability of biobanks, but also raise considerable technical, legal and ethical challenges. What does this paper add?: This paper reports findings from a mixed-methods study of Australian biobanks and reveals contemporary practices and perspectives concerning sample and data sharing, as well as local and global networking. It found most Australian biobanks currently take part in these activities. What are the implications for practitioners?: Many Australian biobanks are networking in various ways across regional and national borders. A better understanding of current practices and views on significant and emerging issues is relevant to the diverse range of biobank stakeholders involved in any agenda to expand biobank networking, including patients, consumers, clinicians, scientists, policy makers and regulators.
- 20 November 2020
- Published by CSIRO Publishing in Australian Health Review
- Vol. 45 (2) , 214-222
Biobank networking and globalisation: perspectives and practices of Australian biobanks
Objective: This study examined the practices and attitudes of Australian biobanks regarding access to samples and data, as well as local and global networking with other biobanks. Methods: This was a mixed-methods study, including an online survey of Australian biobank administrators and qualitative interviews with survey participants. The survey examined the criteria applied when considering requests to share or network. The interviews explored attitudes and practices regarding sharing and networking. Results: Most (90.9%; 30/33) biobanks offered access to their samples and data to others, principally for research (90.6%; 29/32). The most common criteria used to evaluate access requests included ethical oversight (84.8%; 28/33), scientific merit (84.8%; 28/33) and intended use (81.8%; 27/33). Just over two-thirds (69.7%; 23/33) of biobanks participated in Australian networks, and 39.1% (9/23) participated in global networks. Networking took the form of both sharing standardised operating procedures and policies (60.9%) and sharing samples and data (43.5%). Thirteen of the 16 interviewees participated in networks. Motivations for sharing included scientific necessity, sharing expertise and standardising operations and governance. Significant barriers to networking remain, including insufficient resources, inconsistent regulations and procedures, and cultural and political issues to do with the conduct of research. Conclusions: Many Australian biobanks are already active participants in various types of global biobanking. If biobanks are to expand and make the most of their involvement in global networks, then important barriers need to be overcome. What is known about the topic?: Biobanks that store human tissue and associated data are increasingly forming local, national and global networks. These networks create opportunities for enhancing the utility and sustainability of biobanks, but also raise considerable technical, legal and ethical challenges. What does this paper add?: This paper reports findings from a mixed-methods study of Australian biobanks and reveals contemporary practices and perspectives concerning sample and data sharing, as well as local and global networking. It found most Australian biobanks currently take part in these activities. What are the implications for practitioners?: Many Australian biobanks are networking in various ways across regional and national borders. A better understanding of current practices and views on significant and emerging issues is relevant to the diverse range of biobank stakeholders involved in any agenda to expand biobank networking, including patients, consumers, clinicians, scientists, policy makers and regulators.
- 17 August 2020
- Published by SAGE Publications in Public Understanding of Science
- Vol. 29 (7) , 757-769
Examining diversity in public willingness to participate in offshore human biobanking: An Australian mixed methods study
To ensure their sustainability and scientific utility, human biobanks are networking internationally. Sharing biospecimens and associated data across jurisdictions raise a number of practical, ethical, legal and social challenges that could reduce the publics’ willingness to donate their much needed tissue for research purposes. This research aims to identify the impact of biobank location on willingness to donate through a national quantitative survey (n = 750) and 16 in-depth interviews. A latent class analysis in combination with qualitative results suggests that a large proportion of Australians are willing to donate and/or allow their tissue to be stored offshore to help others, but others are reluctant due to uncertainty around foreign ethical and regulatory standards and the loss of potential local benefits. The results highlight for the first time the diversity of public views, and provide important guidance for policy makers and science communicators eager to tailor strategies for specific publics.
- 17 August 2020
- Published by SAGE Publications in Public Understanding of Science
- Vol. 29 (7) , 757-769
Examining diversity in public willingness to participate in offshore human biobanking: An Australian mixed methods study
To ensure their sustainability and scientific utility, human biobanks are networking internationally. Sharing biospecimens and associated data across jurisdictions raise a number of practical, ethical, legal and social challenges that could reduce the publics’ willingness to donate their much needed tissue for research purposes. This research aims to identify the impact of biobank location on willingness to donate through a national quantitative survey (n = 750) and 16 in-depth interviews. A latent class analysis in combination with qualitative results suggests that a large proportion of Australians are willing to donate and/or allow their tissue to be stored offshore to help others, but others are reluctant due to uncertainty around foreign ethical and regulatory standards and the loss of potential local benefits. The results highlight for the first time the diversity of public views, and provide important guidance for policy makers and science communicators eager to tailor strategies for specific publics.
- Open Access
- 15 August 2020
- Published by Springer Nature in BMC Medical Ethics
- Vol. 21 (1) , 1-9
Public trust and global biobank networks
Background: Biobanks provide an important foundation for genomic and personalised medicine. In order to enhance their scientific power and scope, they are increasingly becoming part of national or international networks. Public trust is essential in fostering public engagement, encouraging donation to, and facilitating public funding for biobanks. Globalisation and networking of biobanking may challenge this trust.Methods: We report the results of an Australian study examining public attitudes to the networking and globalisation of biobanks. The study used quantitative and qualitative methods in conjunction with bioethical analysis in order to determine factors that may contribute to, and threaten, trust.Results: Our results indicate a generally high level of trust in biobanks and in medical research more broadly. Key factors that can reduce perceived trustworthiness of biobanks are commercialisation and involvement in global networking.Conclusions: We conclude that robust ethical oversight and governance standards can both promote trust in global biobanking and ensure that this trust is warranted.
- 15 August 2020
- Published by Springer Nature in BMC Medical Ethics
- Vol. 21 (1) , 1-9
Open AccessPublic trust and global biobank networks
Background: Biobanks provide an important foundation for genomic and personalised medicine. In order to enhance their scientific power and scope, they are increasingly becoming part of national or international networks. Public trust is essential in fostering public engagement, encouraging donation to, and facilitating public funding for biobanks. Globalisation and networking of biobanking may challenge this trust.Methods: We report the results of an Australian study examining public attitudes to the networking and globalisation of biobanks. The study used quantitative and qualitative methods in conjunction with bioethical analysis in order to determine factors that may contribute to, and threaten, trust.Results: Our results indicate a generally high level of trust in biobanks and in medical research more broadly. Key factors that can reduce perceived trustworthiness of biobanks are commercialisation and involvement in global networking.Conclusions: We conclude that robust ethical oversight and governance standards can both promote trust in global biobanking and ensure that this trust is warranted.
- 1 January 2020
- Published by American Psychological Association (APA)
Biobank Donation Survey and Interview Measure
- 1 January 2020
- Published by American Psychological Association (APA)
Biobank Donation Survey and Interview Measure